Retatrutide is an experimental triple-agonist injectable medication developed by Eli Lilly and Company that targets GLP-1, GIP, and glucagon receptors. It is currently undergoing Phase 3 clinical trials for chronic weight management and obesity.
How It Works
- Triple Receptor Action: Stimulates GLP-1 and GIP to manage blood sugar and appetite, while adding glucagon receptor activation to increase calorie burning and energy expenditure
- Clinical Efficacy: Phase 3 trials show average weight reductions exceeding 24% to 28% of body weight, alongside improvements in blood pressure, lipids, and liver fat.
-
Status and Safety
- Approval Status: Not yet approved by regulatory bodies like the FDA, pending final Phase 3 trial completions.
- Side Effects: Common reactions include gastrointestinal issues (nausea, diarrhea, vomiting, constipation) and temporary, dose-dependent increases in heart rate.
